Legend Biotech's Key Presentations at the ASH Annual Meeting
Legend Biotech Corporation (NASDAQ: LEGN), a pioneer in cell therapy, is excited to announce a series of transformative presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting. With two oral presentations and seven poster presentations focused on their leading CAR-T therapy, CARVYKTI®, our presentations underscore the ongoing commitment to advancing treatment options for multiple myeloma.
Highlights from the Presentations
The upcoming ASH meeting, taking place from December 6-9, 2025, is set to feature groundbreaking data from our research. Among the highlights is a first-in-human Phase 1 study on Lucar-G39D, an allogeneic CAR-T cell therapy targeting relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) that will be discussed in an oral session. “Our presentations this year demonstrate the depth and innovation in our therapy programs,” remarked Ying Huang, Ph.D., CEO of Legend Biotech.
CARVYKTI: BCA-Targeted Innovation
CARVYKTI is renowned as the first BCMA-targeted CAR-T cell therapy approved for patients who’ve undergone at least one prior line of treatment for multiple myeloma. To date, it has been administered to over 9,000 patients across 14 countries, showcasing its growing global impact.
Key Abstracts at ASH
This year, nine abstracts are spotlighting CARVYKTI, focusing on its durability, evolving safety profile, and real-world outcomes—reiterating its pivotal role in the treatment pathway for multiple myeloma.
Notable Abstracts and Presentations
One of the standout oral presentations is titled “Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed/Refractory Multiple Myeloma,” scheduled for December 6. This presentation will explore the potential long-term benefits of early intervention with CARVYKTI in clinical settings.
Additionally, the abstract “Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With Better Immune Fitness” further supports the concept of timely treatments to optimize patient outcomes through correlative analyses from the CARTITUDE-4 study.
Investigation of Other Therapies
The event will also feature a detailed analysis of Lucar-G39D, discussing its dual-target capabilities against CD20 and CD19 in patients with NHL. This represents our ongoing dedication to pioneering next-generation treatments that may redefine care standards in hematological malignancies.
Ongoing Commitment to Safety
While exploring these groundbreaking findings, patient safety remains a top priority. A section of our presentations will address CARVYKTI’s important safety information, including warnings around cytokine release syndrome and neurological toxicities. We ensure that patients and healthcare providers are well-informed about the benefits and potential risks involved with novel therapies.
About Legend Biotech
With a workforce of over 2,800 dedicated professionals, Legend Biotech is the largest standalone cell therapy company, driving innovations in cancer treatment, particularly through CARVYKTI. Collaborating with Johnson & Johnson, Legend Biotech is committed to broadening access and maximizing patient care across its therapeutic platforms.
Frequently Asked Questions
What is the significance of CARVYKTI in cancer treatment?
CARVYKTI is the first approved BCMA-targeted CAR-T therapy for multiple myeloma, offering significant treatment options for patients after previous therapies.
When and where will the ASH Annual Meeting take place?
The Annual Meeting is scheduled for December 6-9, 2025, with presentations made in Orlando.
What are some topics discussed in the presentations?
Key presentation topics include survival benefits and immune response to Ciltacabtagene Autoleucel, and innovations in next-gen therapies targeting NHL.
How does Legend Biotech ensure patient safety?
Legend Biotech emphasizes patient safety through comprehensive risk assessment and management plans surrounding the administration of therapies like CARVYKTI.
What is Legend Biotech's role in the CAR-T therapy market?
As a leader in cell therapy, Legend Biotech focuses on cutting-edge CAR-T therapeutics, pioneering research, and enhancing therapeutic accessibility while championing patient care.
